AMLX Amylyx Pharmaceuticals, Inc.
FY2025 10-K
Amylyx Pharmaceuticals, Inc. (AMLX) filed its fiscal year 2025 10-K annual report with the SEC on Mar 3, 2026. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.
AI Filing AnalysisFY2025 10-K
Business Overview
- • Core business: Clinical-stage pharma developing novel therapies for endocrine and neurodegenerative diseases with mechanistic rationale and biomarker-driven pipeline
- • New products: Advanced Phase 3 trial for avexitide in PBH; initiated Phase 1 trial for AMX0114 in ALS and selected AMX0318 for long-acting GLP-1 antagonist development
Management Discussion & Analysis
- • Revenue $0 in 2025 vs $87.4M in 2024, 100% decline due to discontinuation of RELYVRIO®/ALBRIOZA™ product sales
- • Operating loss $153.3M in 2025 vs $314.7M in 2024, a 51% improvement; R&D expenses down 13% to $90.4M; SG&A down 45% to $62.9M
Risk Factors
- • Cybersecurity risk oversight by board and executive team with escalation for material incidents to audit committee
- • Dependence on Senior Director of ISGA with CISSP and 20+ years experience for daily information security strategy
Get deeper insights on Amylyx Pharmaceuticals, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.